Inogen Stock (NASDAQ:INGN), Trade Ideas

Inogen

Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.

Earnings

News

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

Markets

Trading Ideas

ADIL

INGN

OGEN

VANI

VTVT

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 100 points on Wednesday.

The Dow traded down 0.27% to 38,867.91 while the NASDAQ fell 0.50% to 15,954.75. The S&amp;P 500 also fell, dropping, 0.18% to 5,068.92.

S&amp;P 500 Edges Lower; ADT Posts Upbeat Earnings

Movers

ACMR

ALHC

ANTE

APLT

BAND

BETS

BIDU

BMBL

BYND

CONNEXA SPORTS TECH INC by Connexa Sports Technologies Inc.

CNXA

CNXC

COCO

CRGE

EBAY

EDIT

FLYW

GTLS

IFBD

IMNN

IXHL

KITT

LAZR

LFST

LMND

MSTR

MVLA

NRDY

NVAX

OCEA

PAYO

PGNY

PSNY

QRTEA

RBOT

RVLV

RXRX

SMXT

TGTX

URBN

VIPS

VTNR

VTYX

Shares of  Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.

Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

bz_pharma_briefs

Guidance

Health Care

General

Inogen reported Q4 2023 revenues of $75.9 million, missing consensus. Despite challenges, the company&#39;s improvements position it well.

Why Is Inogen Stock Plummeting Today?

Inogen Inc

Needham analyst Mike Matson reiterates Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) with a Hold.

Reiteration

Analyst Ratings

Needham Reiterates Hold on Inogen

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 100 points on Wednesday.
The Dow traded down 0.27% to 38,867.91 while the NASDAQ fell 0.50% to 15,954.75. The S&amp;P 500 also fell, dropping, 0.18% to 5,068.92.
Check This Out: <a href="https://www.benzinga.com/news/24/02/37361652/robinhood-shake-shack-and-2-other-stocks-insiders-are-selling"> Robinhood, Shake Shack And 2 Other Stocks Insiders Are Selling</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Real estate shares rose by 1.4% on Wednesday.
In trading on Wednesday, communication services shares fell by 0.8%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
ADT Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/adt#NYSE">ADT</a>) reported better-than-expected earnings for its fourth quarter on Wednesday.
ADT posted fourth-quarter fiscal 2023 sales decline of 7.2% year-on-year to $1.22 billion, missing the consensus of $1.44 billion. Adjusted EPS was 25 cents, beating the consensus of 4 cents.
ADT expects CSB segment revenue of 4.8 billion-$5.0 billion. The company expects adjusted EPS of $0.60 &ndash; $0.70, against consensus of $0.50.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Vivani Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vani#NASDAQ">VANI</a>) shares shot up 274% to $3.78 after the company announced preclinical data on weight loss effects for NPM-115 and disclosed that semaglutide is the active pharmaceutical ingredient in NPM-139.
Shares of Adial Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adil#NASDAQ">ADIL</a>) got a boost, surging 159% to $2.1917. Adial Pharmaceuticals secured new US patent covering lead product for alcohol use disorder.
vTv Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtvt#NASDAQ">VTVT</a>) shares were also up, gaining 117% to $18.05 after the company announced a $51 million private placement from healthcare-focused institutional investors and the JDRF T1D Fund.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Oragenics, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ogen#NYSE">OGEN</a>) shares dropped 42% to $1.42. Oragenics priced its public offering 1.4 million common shares at $1.50 per share for gross proceeds of $2.1 million.
Shares of Integral Ad Science Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ias#NASDAQ">IAS</a>) were down 42% to $9.92 after the company reported fourth-quarter financial results.
Inogen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ingn#NASDAQ">INGN</a>) was down, falling 35% to $6.08 following weak quarterly results.
Also Check This Out:<a href="https://www.benzinga.com/news/24/02/37334066/top-3-energy-stocks-that-could-sink-your-portfolio-in-q1"> Top 3 Energy Stocks That Could Sink Your Portfolio In Q1 </a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 0.3% to $78.65 while gold traded down 0.2% at $2,040.40.
Silver traded fell 0.5% to $22.645 on Wednesday while copper fell 0.3% to $3.8390.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mostly lower today. The eurozone&rsquo;s STOXX 600 fell 0.35%, London&rsquo;s FTSE 100 fell 0.76% while Spain&rsquo;s IBEX 35 Index fell 0.45% The German DAX gained 0.25% French CAC 40 rose 0.08% while Italy&rsquo;s FTSE MIB Index declined 0.27%.
The services confidence indicator in the Eurozone fell to 6 in February, the lowest in three months, while economic sentiment indicator fell to 95.4 in February. The consumer confidence indicator in the Eurozone increased by 0.6 points to a reading of -15.5 in February.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed lower on Wednesday, with Japan&rsquo;s Nikkei 225 falling 0.08%, Hong Kong&rsquo;s Hang Seng Index dipping 1.51%, China&rsquo;s Shanghai Composite Index tumbling 1.91% and India&rsquo;s S&amp;P BSE Sensex falling 1.08%.
Hong Kong&rsquo;s GDP increased by 4.3% year-over-year in the fourth quarter, up from a 4.1% increase in the prior period. The index of leading economic indicators in Japan was revised higher to 110.2 in December versus preliminary reading of 110, while index of coincident economic indicators was revised lower to 115.9 in December versus a flash reading of 116.2.
&nbsp;
<h3>Economics</h3>
&nbsp;
U.S. mortgage applications fell by 5.6% on the week ending Feb. 23.
The U.S. economy grew an annualized 3.2% in the fourth quarter, versus a 4.9% rate in the previous quarter.
The U.S. trade deficit in goods rose to $90.20 billion in January versus a revised $87.89 billion in the prior month.
U.S. wholesale inventories declined by 0.1% month-over-month in January following a 0.4% increase a month ago.
U.S. crude oil inventories increased by 4.199 million barrels in the week ending Feb. 23, versus market estimates of a 2.743 million gain, the EIA said.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/02/37356403/cramer-says-this-ai-stock-is-just-an-nvidia-play-prefers-this-stock-over-anheuser-busch"> Cramer Says This AI Stock Is Just An Nvidia Play, Prefers This Stock Over Anheuser-Busch </a>

S&P 500 Edges Lower; ADT Posts Upbeat Earnings

Shares of Bumble Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bmbl#NASDAQ">BMBL</a>) fell sharply during Wednesday&rsquo;s session <a href="https://www.benzinga.com/news/earnings/24/02/37349026/bumble-reports-q4-results-eps-miss-revenue-miss-workforce-reductions">following weak quarterly results</a>.
Bumble reported quarterly losses of 19 cents per share which missed the analyst consensus estimate of 12 cents per share. The company reported quarterly sales of $273.64 million which missed the analyst consensus estimate of $275.29 million.
Bumble shares dipped 11.6% to $11.65 on Wednesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Vivani Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vani#NASDAQ">VANI</a>) shares jumped 289% to $3.93 after the company announced preclinical data on weight loss effects for NPM-115 and disclosed that semaglutide is the active pharmaceutical ingredient in NPM-139.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adil#NASDAQ">ADIL</a>) climbed 190% to $2.4598. Adial Pharmaceuticals secured new US patent covering lead product for alcohol use disorder.</li>
<li>vTv Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtvt#NASDAQ">VTVT</a>) gained 112% to $17.65 after the company announced a $51 million private placement from healthcare-focused institutional investors and the JDRF T1D Fund.</li>
<li>Bit Brother Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bets#NASDAQ">BETS</a>) shares rose 63.7% to $4.0750.</li>
<li>Beyond Meat, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bynd#NASDAQ">BYND</a>) climbed 45% to $10.90 as the company reported stronger-than-expected sales for its fourth quarter.</li>
<li>Incannex Healthcare Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ixhl#NASDAQ">IXHL</a>) gained 43.6% to $6.06 after the company announced its Psi-GAD1 trial met its primary endpoint.</li>
<li>Bandwidth Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/band#NASDAQ">BAND</a>) surged 43.3% to $17.41 after the company reported better-than-expected fourth quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Imunon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imnn#NASDAQ">IMNN</a>) climbed 38% to $0.98.</li>
<li>Applied Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aplt#NASDAQ">APLT</a>) surged 36% to $7.59 after the company announced FDA acceptance and priority review of the NDA for govorestat for the treatment of Classic Galactosemia. The company also announced a $100 million private placement.</li>
<li>Movella Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mvla#NASDAQ">MVLA</a>) gained 33.5% to $0.33.</li>
<li>LifeStance Health Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lfst#NASDAQ">LFST</a>) gained 31.5% to $8.81 following strong quarterly sales.</li>
<li>AirNet Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ante#NASDAQ">ANTE</a>) rose 31.3% to $1.05. AirNet announced changes in senior management team.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/psny#NASDAQ">PSNY</a>) rose 29.9% to $1.9350. Polestar secured $1 billion external funding.</li>
<li>Editas Medicine, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/edit#NASDAQ">EDIT</a>) gained 27.7% to $11.31 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>TG Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tgtx#NASDAQ">TGTX</a>) jumped 27.2% to $17.69 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Qurate Retail, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qrtea#NASDAQ">QRTEA</a>) rose 22% to $1.71 after the company reported fourth-quarter financial results.</li>
<li>B&amp;G Foods, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bgs#NYSE">BGS</a>) gained 21.4% to $11.41 after the company reported better-than-expected fourth-quarter financial results and issued FY24 revenue guidance.</li>
<li>Flywire Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flyw#NASDAQ">FLYW</a>) gained 20% to $29.40 after the company reported better-than-expected fourth quarter financial results.</li>
<li>Flywire Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flyw#NASDAQ">FLYW</a>) climbed 17.6% to $28.84 after the company reported better-than-expected fourth quarter financial results.</li>
<li>The Vita Coco Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coco#NASDAQ">COCO</a>) surged 17.3% to $26.32 after the company reported better-than-expected fourth-quarter financial results and issued FY24 net sales guidance.</li>
<li>J-Long Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jl#NASDAQ">JL</a>) gained 17.2% to $18.90.</li>
<li>Revolve Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rvlv#NYSE">RVLV</a>) rose 16% to $20.28 as the company reported upbeat results for its fourth quarter on Tuesday.</li>
<li>Nauticus Robotics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kitt#NASDAQ">KITT</a>) gained 15.9% to $0.3549.</li>
<li>Life Time Group Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lth#NYSE">LTH</a>) gained 15.3% to $14.32 after the company reported better-than-expected fourth quarter financial results and issued first-quarter revenue guidance above estimates.</li>
<li>Ventyx Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtyx#NASDAQ">VTYX</a>) shares jumped 15% to $6.96 in pre-market trading following fourth-quarter results.</li>
<li>Connexa Sports Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cnxa#NASDAQ">CNXA</a>) shares jumped 14.3% to $0.27.</li>
<li>ACM Research, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acmr#NASDAQ">ACMR</a>) rose 13.6% to $24.75 in pre-market trading after the company reported better-than-expected fourth-quarter FY23 results.</li>
<li>Vipshop Holdings Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vips#NYSE">VIPS</a>) gained 12.4% to $19.49 after the company reported better-than-expected fourth quarter financial results.</li>
<li>MicroStrategy Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mstr#NASDAQ">MSTR</a>) climbed 10.9% to $967.01.</li>
<li>Chart Industries, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gtls#NASDAQ">GTLS</a>) rose 10.5% to $145.33 after the company reported mixed fourth quarter financial results and issued FY24 adjusted EPS guidance above estimates.</li>
<li>Assured Guaranty Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ago#NYSE">AGO</a>) gained 9.8% to $94.11 following fourth quarter financial results.</li>
<li>eBay Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ebay#NASDAQ">EBAY</a>) rose 8.4% to $48.15 after the company reported better-than-expected fourth quarter financial results.</li>
<li>ADT Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/adt#NYSE">ADT</a>) climbed 7.2% to $7.00 following upbeat earnings.</li>
<li>Advance Auto Parts, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aap#NYSE">AAP</a>) gained 7.1% to $69.32 fourth quarter financial results.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Oragenics, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ogen#NYSE">OGEN</a>) shares fell 43.3% to $1.39. Oragenics priced its public offering 1.4 million common shares at $1.50 per share for gross proceeds of $2.1 million.</li>
<li>Integral Ad Science Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ias#NASDAQ">IAS</a>) fell 40.2% to $1.39 after the company reported fourth-quarter financial results.</li>
<li>Charge Enterprises, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crge#NASDAQ">CRGE</a>) fell 36.8% to $0.0379.</li>
<li>Palatin Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ptn#NYSE">PTN</a>) fell 34.8% to $2.5880 after the company reported results of PL9643 MELODY-1 pivotal Phase 3 clinical trial in patients with dry eye disease.</li>
<li>Inogen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ingn#NASDAQ">INGN</a>) dipped 31.2% to $6.43 following weak results.</li>
<li>Eventbrite, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eb#NYSE">EB</a>) fell 30.2% to $5.81 after the company reported mixed fourth-quarter financial results.</li>
<li>Solarmax Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smxt#NASDAQ">SMXT</a>) shares fell 27.5% to $5.81. SolarMax Technology announced pricing of initial public offering and listing on Nasdaq.</li>
<li>Novavax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvax#NASDAQ">NVAX</a>) dipped 27% to $4.4000 after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter revenue guidance below estimates.</li>
<li>Lemonade, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lmnd#NYSE">LMND</a>) shares declined 26.1% to $16.04 after the company reported fourth-quarter financial results.</li>
<li>Vicarious Surgical Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rbot#NYSE">RBOT</a>) fell 24% to $0.4099 after jumping 57% on Tuesday.</li>
<li>Ocean Biomedical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocea#NASDAQ">OCEA</a>) dipped 21.9% to $1.53.</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) fell 21.8% to $1.00.</li>
<li>3D Systems Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ddd#NYSE">DDD</a>) fell 21.6% to $4.10 following weak fourth-quarter financial results.</li>
<li>Nerdy, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nrdy#NYSE">NRDY</a>) fell 21% to $2.4099 following fourth-quarter financial results.</li>
<li>Vertex Energy, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vtnr#NYSE">VTNR</a>) shares dipped 20.7% to $1.3310 after posting a fourth-quarter loss.</li>
<li>Alignment Healthcare, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alhc#NASDAQ">ALHC</a>) fell 17.5% to $5.71 after the company reported worse-than-expected fourth-quarter GAAP EPS results.</li>
<li>Progyny, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pgny#NASDAQ">PGNY</a>) fell 17.2% to $33.79 after the company reported mixed fourth-quarter financial results.</li>
<li>The Boston Beer Company, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sam#NYSE">SAM</a>) dipped 17.1% to $306.80 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Payoneer Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/payo#NASDAQ">PAYO</a>) fell 15.6% to $4.69 after the company issued FY24 revenue guidance below estimates.</li>
<li>Concentrix Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cnxc#NASDAQ">CNXC</a>) fell 15.3% to $70.25.</li>
<li>Urban Outfitters, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/urbn#NASDAQ">URBN</a>) shares declined 15% to $40.08 after the company reported fourth-quarter financial results.</li>
<li>Hyster-Yale Materials Handling, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hy#NYSE">HY</a>) fell 14.1% to $60.20 following fourth-quarter results.</li>
<li>The E.W. Scripps Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ssp#NASDAQ">SSP</a>) fell 12.2% to $4.1050 after the company reported mixed fourth-quarter financial results.</li>
<li>Luminar Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lazr#NASDAQ">LAZR</a>) dipped 10% to $2.25 following downbeat quarterly results.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rxrx#NASDAQ">RXRX</a>) shares fell 9.1% to $14.10 after the company reported mixed fourth-quarter financial results.</li>
<li>Baidu, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bidu#NASDAQ">BIDU</a>) fell 7.1% to $104.42 after the company reported financial Q4 results.</li>
<li>Macy&#39;s, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/m#NYSE">M</a>) fell 4.8% to $18.99.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/02/37366156/snowflake-gears-up-for-q4-print-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-cal"> Snowflake Gears Up For Q4 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call </a>

Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Inogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>), a medical technology company, reported fourth-quarter 2023 revenues of $75.90 million, missing the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $76.99 million</a>.
Fourth quarter total revenue fell from $88.1 million in the fourth quarter of 2022. This was primarily due to a decrease in domestic business-to-business and direct-to-consumer sales, partially offset by <a href="https://www.benzinga.com/pressreleases/24/02/b37347241/inogen-announces-fourth-quarter-and-full-year-2023-financial-results" target="_blank" rel="noreferrer noopener">higher rental revenue</a>.
Inogen reported an adjusted EPS loss of $(0.83). While the company missed the consensus of $(0.62), it reported higher than the $(0.57) reported a year ago.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37166065/competitor-exit-a-boom-for-respiratory-device-focused-inogen-earns-analyst-upgrade" target="_blank" rel="noreferrer noopener">Competitor Exit A Boom For Respiratory Device-Focused Inogen, Earns Analyst Upgrade</a>.
Guidance:&nbsp;Inogen expects first quarter 2024 revenue of $73 million-$74 million versus the consensus of $80.63 million.
William Blair acknowledges the uncertainties in international tenders and the company&#8217;s commercial strategy adjustments, such as discontinuing a third-party rental partnership.&nbsp;
Despite these challenges, the analyst writes that the provided guidance is realistic and potentially surpassable under the new management team.&nbsp;
There are positive indicators of market improvement and Inogen&#8217;s enhanced market position, particularly with a significant competitor exiting.
Specific market share figures for Respironics before its January exit from the POC market were not disclosed. Inogen is described as a market leader with an estimated 40%-50% share. 
The departure of the competitor has created an opportunity for Inogen to capture additional market share (estimated at 15%-25% for Respironics). Although this potential benefit is not included in the first-quarter guidance, management has indicated early interest from some HME customers.
William Blair reiterates the&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/INGN/analyst-ratings" rel="noreferrer noopener">Outperform rating in the stock</a>.
Price Action:&nbsp;INGN shares are down 31.1% at $6.44 on the last check Wednesday.

<h3>Gainers</h3>
<ul>
<li>Vivani Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) stock increased by 314.4% to $4.19 during Wednesday's regular session. The company's market cap stands at $213.5 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock moved upwards by 157.73% to $2.25. The market value of their outstanding shares is at $3.7 million. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares moved upwards by 105.88% to $17.5. The market value of their outstanding shares is at $35.6 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares increased by 40.27% to $0.71. The company's market cap stands at $6.6 million. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares rose 36.61% to $0.97. The company's market cap stands at $9.1 million. </li>
<li>G1 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTHX#NASDAQ">GTHX</a>) stock rose 35.2% to $3.25. The market value of their outstanding shares is at $168.2 million. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) stock declined by 42.9% to $1.4 during Wednesday's regular session. The company's market cap stands at $4.3 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock declined by 37.41% to $2.48. The market value of their outstanding shares is at $40.0 million. </li>
<li>Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) stock declined by 35.44% to $6.03. The market value of their outstanding shares is at $140.5 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) stock decreased by 27.41% to $4.37. The market value of their outstanding shares is at $519.1 million. As per the news, the Q4 earnings report came out today. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) shares fell 24.41% to $0.41. The market value of their outstanding shares is at $71.3 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock fell 23.47% to $1.5. The company's market cap stands at $51.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSGM

GTHX

12 Health Care Stocks Moving In Wednesday's Intraday Session

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 50 points on Wednesday.
The Dow traded down 0.19% to 38,899.92 while the NASDAQ fell 0.31% to 15,985.25. The S&amp;P 500 also fell, dropping, 0.11% to 5,072.67.
Check This Out: <a href="https://www.benzinga.com/news/24/02/37361652/robinhood-shake-shack-and-2-other-stocks-insiders-are-selling"> Robinhood, Shake Shack And 2 Other Stocks Insiders Are Selling</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Real estate shares rose by 1.1% on Wednesday.
In trading on Wednesday, health care shares fell by 0.8%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
U.S. crude oil inventories increased by 4.199 million barrels in the week ending Feb. 23, versus market estimates of a 2.743 million gain, the EIA said.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Vivani Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vani#NASDAQ">VANI</a>) shares shot up 301% to $4.05 after the company announced preclinical data on weight loss effects for NPM-115 and disclosed that semaglutide is the active pharmaceutical ingredient in NPM-139.
Shares of Adial Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adil#NASDAQ">ADIL</a>) got a boost, surging 164% to $2.2350. Adial Pharmaceuticals secured new US patent covering lead product for alcohol use disorder.
vTv Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtvt#NASDAQ">VTVT</a>) shares were also up, gaining 136% to $19.61 after the company announced a $51 million private placement from healthcare-focused institutional investors and the JDRF T1D Fund.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Oragenics, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ogen#NYSE">OGEN</a>) shares dropped 43% to $1.40. Oragenics priced its public offering 1.4 million common shares at $1.50 per share for gross proceeds of $2.1 million.
Shares of Integral Ad Science Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ias#NASDAQ">IAS</a>) were down 41% to $10.15 after the company reported fourth-quarter financial results.
Inogen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ingn#NASDAQ">INGN</a>) was down, falling 35% to $6.12 following weak quarterly results.
Also Check This Out:<a href="https://www.benzinga.com/news/24/02/37334066/top-3-energy-stocks-that-could-sink-your-portfolio-in-q1"> Top 3 Energy Stocks That Could Sink Your Portfolio In Q1 </a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 0.6% to $78.38 while gold traded down 0.1% at $2,043.80.
Silver traded fell 0.5% to $22.645 on Wednesday while copper fell 0.3% to $3.8390.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mostly lower today. The eurozone&rsquo;s STOXX 600 fell 0.35%, London&rsquo;s FTSE 100 fell 0.76% while Spain&rsquo;s IBEX 35 Index fell 0.45% The German DAX gained 0.25% French CAC 40 rose 0.08% while Italy&rsquo;s FTSE MIB Index declined 0.27%.
The services confidence indicator in the Eurozone fell to 6 in February, the lowest in three months, while economic sentiment indicator fell to 95.4 in February. The consumer confidence indicator in the Eurozone increased by 0.6 points to a reading of -15.5 in February.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed lower on Wednesday, with Japan&rsquo;s Nikkei 225 falling 0.08%, Hong Kong&rsquo;s Hang Seng Index dipping 1.51%, China&rsquo;s Shanghai Composite Index tumbling 1.91% and India&rsquo;s S&amp;P BSE Sensex falling 1.08%.
Hong Kong&rsquo;s GDP increased by 4.3% year-over-year in the fourth quarter, up from a 4.1% increase in the prior period. The index of leading economic indicators in Japan was revised higher to 110.2 in December versus preliminary reading of 110, while index of coincident economic indicators was revised lower to 115.9 in December versus a flash reading of 116.2.
&nbsp;
<h3>Economics</h3>
&nbsp;
U.S. mortgage applications fell by 5.6% on the week ending Feb. 23.
The U.S. economy grew an annualized 3.2% in the fourth quarter, versus a 4.9% rate in the previous quarter.
The U.S. trade deficit in goods rose to $90.20 billion in January versus a revised $87.89 billion in the prior month.
U.S. wholesale inventories declined by 0.1% month-over-month in January following a 0.4% increase a month ago.
U.S. crude oil inventories increased by 4.199 million barrels in the week ending Feb. 23, versus market estimates of a 2.743 million gain, the EIA said.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/02/37356403/cramer-says-this-ai-stock-is-just-an-nvidia-play-prefers-this-stock-over-anheuser-busch"> Cramer Says This AI Stock Is Just An Nvidia Play, Prefers This Stock Over Anheuser-Busch </a>

Nasdaq Down 50 Points; US Crude Stocks Rise By 4.2M Barrels

Inogen Shares Resume Trade

Inogen Shares Halted On Circuit Breaker To The Downside, Stock Now Down -33.5%

<h3>Gainers</h3>
<ul>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares increased by 104.2% to $17.36 during Wednesday's pre-market session. The market value of their outstanding shares is at $35.3 million. </li>
<li>Vivani Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) stock moved upwards by 67.32% to $1.69. The company's market cap stands at $86.2 million. </li>
<li>Genetic Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENE#NASDAQ">GENE</a>) shares moved upwards by 17.52% to $2.28. The market value of their outstanding shares is at $8.7 million. </li>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock moved upwards by 14.28% to $0.8. The market value of their outstanding shares is at $15.8 million. </li>
<li>Ventyx Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) shares moved upwards by 12.89% to $6.83. The company's market cap stands at $403.2 million. The company's, Q4 earnings came out yesterday. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares moved upwards by 12.08% to $0.8. The market value of their outstanding shares is at $7.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) stock fell 45.3% to $1.34 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.1 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock decreased by 34.26% to $2.61. The company's market cap stands at $42.1 million. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) shares declined by 21.43% to $0.42. The company's market cap stands at $74.2 million. </li>
<li>ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) shares declined by 15.73% to $1.34. The company's market cap stands at $90.9 million. </li>
<li>Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) shares fell 14.46% to $7.99. The market value of their outstanding shares is at $186.2 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) stock fell 13.63% to $5.2. The market value of their outstanding shares is at $617.7 million. As per the press release, Q4 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GENE

PROK

PRTG

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Inogen Sees Q1 2024 Revenue $73M-$74M Vs $80.63M Estimate

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.62) by 33.87 percent. This is a 45.61 percent decrease over losses of $(0.57) per share from the same period last year. The company reported quarterly sales of $75.90 million which missed the analyst consensus estimate of $76.99 million by 1.42 percent. This is a 13.84 percent decrease over sales of $88.09 million the same period last year.

Earnings Misses

Inogen Q4 2023 Adj EPS $(0.83) Misses $(0.62) Estimate, Sales $75.90M Miss $76.99M Estimate

<h3>Gainers</h3>
<ul>
<li>Lexaria Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXX#NASDAQ">LEXX</a>) shares rose 10.0% to $2.64 during Tuesday's after-market session. The market value of their outstanding shares is at $32.2 million. </li>
<li>China Pharma Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock moved upwards by 7.5% to $0.08. The company's market cap stands at $4.1 million. </li>
<li>Ventyx Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) shares increased by 7.42% to $6.5. The company's market cap stands at $383.7 million. </li>
<li>Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) shares increased by 5.73% to $140.15. The market value of their outstanding shares is at $41.0 billion. As per the press release, Q1 earnings came out today. </li>
<li>Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) shares moved upwards by 5.68% to $1.86. The market value of their outstanding shares is at $237.1 million. </li>
<li>BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) shares increased by 5.12% to $3.49. The market value of their outstanding shares is at $106.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) shares decreased by 24.1% to $0.41 during Tuesday's after-market session. The market value of their outstanding shares is at $71.7 million. </li>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) stock declined by 10.5% to $5.8. The company's market cap stands at $2.3 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) stock fell 9.67% to $14.02. The company's market cap stands at $3.0 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Progyny (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>) stock declined by 9.32% to $36.99. The company's market cap stands at $3.5 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) stock declined by 8.46% to $8.55. The company's market cap stands at $199.2 million. As per the news, the Q4 earnings report came out today. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares decreased by 7.42% to $0.87. The company's market cap stands at $4.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BTAI

CMPX

CPHI

LEXX

VERO

12 Health Care Stocks Moving In Tuesday's After-Market Session

ACAD

ACHC

AESI

AHCO

AIRS

ALEC

AMBA

AMBC

APLS

ARKO

ARQT

ARRY

ATEC

AXON

BCSF

BECN

BGFV

BWXT

CAVA

CBRL

CIVI

CLDT

CLNE

CLVT

CMLS

COMP

CPNG

CRDO

CYTK

EHTH

ESPR

FARO

FOUR

FSLR

FULC

GDOT

GLPI

GMRE

GSX Techedu Inc. American Depositary Shares

GOTU

GPOR

HRZN

HSIC

HURN

ICCC

ICFI

ICUI

IMAX

IMXI

INSE

IPAR

JAMF

KIND

KURA

KVYO

LGND

LGVN

Earnings Scheduled For February 27, 2024

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-02-27. Here's what investors need to know before the announcement.
Analysts estimate that Inogen will report an earnings per share (EPS) of $-0.62. 
Inogen bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.13, which was followed by a 1.14% drop in the share price the next day.
Here's a look at Inogen's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.49</td>
<td>-0.64</td>
<td>-0.81</td>
<td>-0.57</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.36</td>
<td>-0.25</td>
<td>-0.63</td>
<td>-0.57</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-14.000000000000002%</td>
<td>-5.0%</td>
<td>-31.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1708977699_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Inogen were trading at $9.19 as of February 23. Over the last 52-week period, shares are down 40.97%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/INGN/earnings">To track all earnings releases for Inogen visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Inogen Earnings Preview

In January,&nbsp;&nbsp;Koninklijke Philips NV&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) announced that it would stop selling new CPAP or BiPAP sleep therapy devices or other respiratory care devices in the U.S. until the consent decree&#8217;s&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/01/36822576/dutch-health-tech-firm-philips-stops-us-sales-of-respiratory-devices-under-finalized-consent-decree" rel="noreferrer noopener">requirements are met</a>.
Internationally, Philips Respironics will maintain its provision of new sleep and respiratory care devices, along with associated accessories, consumables, replacement parts, and services, subject to specific conditions.&nbsp;
William Blair&nbsp;writes that&nbsp;Inogen Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) has a significant opportunity to regain a substantial portion of the forfeited market share.&nbsp;
The analysis suggests that Respironics was the second-largest player in the market, with an estimated 15%-25% share. William Blair expects Inogen to have roughly a 50% share in the market compared to Respironics.
In a pessimistic scenario, this departure could counteract potential challenges faced by Inogen due to recent execution issues or worsening macroeconomic conditions.&nbsp;
On the other hand, in an optimistic scenario, Respironics&#8217; exit presents a substantial opportunity for Inogen to enhance its financial performance and secure a stronger position in the market.
Despite recent changes in strategy and management, including the appointment of a new CEO and CFO in recent months, the company&#8217;s stability in fundamentals and commercial organization remains uncertain, the analyst writes.&nbsp;
However, given the current valuation, the risk/reward balance is perceived as favorable. Hence, William Blair upgraded Inogen from&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/INGN/analyst-ratings" rel="noreferrer noopener">Market Perform to Outperform</a>.
The upgrade is based on the potential for capturing new shares, a valuation disconnect compared to the lowest quartile of peers, and the company&#8217;s sufficient capital for at least two years, which could bridge it to financing or profitability.
Price Action: INGN shares are up 22.9% at $10.46 on the last check Thursday.

Analyst Color

Equities

Upgrades

Competitor Exit A Boom For Respiratory Device-Focused Inogen, Earns Analyst Upgrade

<h3>Gainers</h3>
<ul>
<li>Sientra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIEN#NASDAQ">SIEN</a>) stock rose 193.5% to $0.53 during Thursday's regular session. The market value of their outstanding shares is at $6.3 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) stock increased by 28.78% to $2.55. The market value of their outstanding shares is at $11.0 million. </li>
<li>Orgenesis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGS#NASDAQ">ORGS</a>) stock increased by 23.78% to $0.42. The company's market cap stands at $13.4 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock rose 23.1% to $0.14. The company's market cap stands at $3.9 million. </li>
<li>Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) stock increased by 20.44% to $10.25. The market value of their outstanding shares is at $238.9 million. </li>
<li>American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) shares rose 18.91% to $1.32. The company's market cap stands at $379.5 million. The company's, Q4 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) stock decreased by 32.2% to $0.82 during Thursday's regular session. The market value of their outstanding shares is at $40.9 million. The company's, Q2 earnings came out yesterday. </li>
<li>Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) stock decreased by 28.88% to $0.66. The company's market cap stands at $251.7 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock decreased by 21.02% to $3.27. The company's market cap stands at $52.7 million. As per the press release, Q2 earnings came out yesterday. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock fell 20.73% to $2.83. The company's market cap stands at $12.1 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) shares decreased by 18.06% to $2.27. The market value of their outstanding shares is at $14.5 million. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) shares fell 15.92% to $0.38. The company's market cap stands at $8.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGEN

AMWL

FRES

HCTI

HEPA

ORGS

RNLX

SIEN

SYRA

12 Health Care Stocks Moving In Thursday's Intraday Session

William Blair analyst Margaret Kaczor upgrades Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) from Market Perform to Outperform.

William Blair Upgrades Inogen to Outperform

Inogen, Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ingn#NASDAQ">INGN</a>) shares are trading higher on Wednesday. Earlier in the day, Citron Research posted a tweet about the company <a href="https://www.benzinga.com/pressreleases/24/01/b36767332/inogen-names-michael-bourque-as-new-chief-financial-officer">on its X account</a>.
What To Know: At 10:33 am EST on Wednesday, Citron Research made a <a href="https://twitter.com/CitronResearch/status/1752716775521738962">post </a>about Inogen on X, saying: &quot;$INGN Game Changing News- That Until Now Has Gone Unnoticed By Wall Street. Phillips the #2 players in POC Machines has unexpectantly exited the market.&quot;
Prior to the tweet, shares of Inogen had risen by over 10%, with the stock rising almost another 7% after it was posted.
The stock has trended gradually higher since November with shares rallying again at the end of January after a pullback during the middle of the month.
Despite the recent gains, Inogen stock is down approximately 70% over the past year.
Related Link: <a href="https://www.benzinga.com/markets/cryptocurrency/24/01/36868163/germany-seizes-over-2-billion-in-bitcoin-from-piracy-proceeds">Germany Seizes Over $2 Billion In Bitcoin From Piracy Proceeds</a>
INGN Price Action: Shares of Inogen were up 13.5% at $7.19 at the time of publication, according to <a href="http://pro.benzinga">Benzinga Pro</a>.
Image by <a href="https://pixabay.com/users/parentingupstream-1194855/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=840125">Parentingupstream</a> from <a href="https://pixabay.com//?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=840125">Pixabay</a> 
<img alt="" src="https://www.benzinga.com/files/u1437295/newplot26.png" style="height:650px; width:750px" />
&nbsp;

Inogen Gets A Shout-Out From Citron Research On X: Here's What's Happening

Watching Inogen Shares After Citron Research Tweets '$INGN Game Changing News- That Until Now Has Gone Unnoticed By Wall Street. Phillips the #2 players in POC Machines has unexpectantly exited the market'

Management

Inogen Names Michael Bourque As CFO Effective March 4, 2024

Inogen GAAP EPS of -$1.14 misses by $0.51, revenue of $75.9M misses by $1.02M

Inogen, Inc. (INGN) Q4 2023 Earnings Call Transcript

Inogen, Inc. 2023 Q4 - Results - Earnings Call Presentation

Needham analyst Michael Matson maintained a Hold rating on Inogen (INGN – Research Report) today. The company's shares closed yesterday at $9.34. M...

Needham Remains a Hold on Inogen (INGN)

Inogen Inc (INGN) said after close Tuesday that it lost $0.83 per share in quarter four 2023. The company reported earnings on an adjusted basis, so it may not be directly comparable to analyst estimates or prior periods.On the revenue line, the company reported $75.9 million, missing estimates by $1.1 million.In the same

Inogen Inc Down 33.51% To $6.21 After Earnings Miss

CNDB and SOND among mid-day movers

These Healthcare stocks are trading higher:-Vivani Medical Inc (VANI) stock is trading at $4.59, a gain of $3.58, or 362.97%, on high volume.  Vivani Medical Inc gets a Sentiment Score of Very Bearish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $4.00. Vivani Me

Healthcare Stocks on the Move Wednesday: VANI, ADIL, VTVT, IXHL, OGEN, PTN, INGN, NVAX

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Inogen (INGN – Research Report) and Galectin Therapeutics (GALT –...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Inogen (INGN) and Galectin Therapeutics (GALT)

-

-

-

-

-

-

-

25% Off Benzinga's Most Powerful Trading Tools

-

-

-

-

-

-

-

Inogen Stock (NASDAQ:INGN), Trade Ideas